Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: pediatric

European Medicines Agency Committee Issues Positive Opinion for Secukinumab in Pediatric Arthritic Disease

Michele B. Kaufman, PharmD, BCGP  |  June 2, 2022

In the E.U., secukinumab is edging closer to approval for use in pediatric patients with juvenile idiopathic arthritis (JIA), specifically those with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (PsA). In May, the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion on expanding its indications.

Filed under:ConditionsDrug UpdatesPediatric ConditionsPsoriatic Arthritis Tagged with:enthesitis-related arthritis (ERA)European UnionJIAjuvenile idiopathic arthritis (JIA)juvenile PsAPediatricPediatric RheumatologyPsAPsoriatic Arthritissecukinumab

Supporting Rheumatologic Care for Pediatric Patients

Mary Beth Nierengarten  |  January 10, 2022

As chair of the Pediatric Rheumatology Special Committee, Colleen Correll, MD, MPH, is supporting efforts to increase the pediatric rheumatology workforce as a whole and pediatric rheumatology representation in the ACR.

Filed under:Profiles Tagged with:ACR’s Pediatric Rheumatology Special CommitteeColleen CorrellWorkforce

Pediatric Rheumatology Year in Review, 2021: Basic Science

Elizabeth Sloan, MD  |  December 9, 2021

ACR Convergence 2021—The field of pediatric rheumatology has benefited from significant developments in the basic and translational sciences over the past year, and it can be challenging to keep up with the latest discoveries. In the Basic Science section of the Pediatric Rheumatology Year in Review at ACR Convergence, Tiphanie Vogel, MD, PhD, assistant professor…

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric ConditionsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2021ACR Convergence 2021 – SLECOVID-19DADA2Pediatric

The State of Clinical Science for Pediatric Rheumatology in 2021

Elizabeth Sloan, MD  |  December 2, 2021

ACR Convergence 2021—The Pediatric Rheumatology Year in Review began with a fascinating talk by Mara Becker, MD, MSCE, a professor of Pediatrics and vice chair of faculty at Duke University School of Medicine, Durham, N.C. Dr. Becker began by describing her search strategy to select high-yield clinical science publications in pediatric rheumatology from the past…

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric Conditions Tagged with:ACR Convergence 2021ClinicalCOVID-19JIAMultisystem Inflammatory Syndrome in Children (MIS-C)PediatricPediatric Rheumatologypolyarticular juvenile idiopathic arthritis (JIA)

How Pediatric Rheumatologists Are Moving Lupus Research Forward

Elizabeth Sloan, MD  |  November 23, 2021

In the 2021 Edmund L. Dubois, MD, Memorial Lectureship, Aimee Hersh, MD, discussed her work on defining research priorities in pediatric lupus.

Filed under:ACR ConvergenceConditionsMeeting ReportsPediatric ConditionsSystemic Lupus Erythematosus Tagged with:ACR Convergence 2021ACR Convergence 2021 – SLEchildhood-onset SLEPediatricPediatric RheumatologySLEsystemic lupus erythematosus (SLE)

The Art & Science of Imaging the Pediatric Sacroiliac Joint

Lara C. Pullen, PhD  |  November 3, 2021

Additional training may be needed on the appearance of the maturing sacroiliac (SI) joint on MRI. In a recent study, researchers found local radiologists may mistake normal physiologic changes of a maturing SI joint as sacroiliitis in pediatric patients.

Filed under:ConditionsPediatric Conditions Tagged with:imagingjoint imagingPediatricRadiologistsacroiliac jointssacroiliitisSI joint

Tips for Transitioning Patients from Pediatric to Adult Rheumatology Care

Sarah D. Bayefsky, MD, Kimberly DeQuattro, MD, & Rebecca E. Sadun, MD, PhD  |  October 14, 2021

Approximately 50% of young adult patients with childhood-onset rheumatic diseases become lost to follow-up within the first year of transferring to adult rheumatology care, mirroring the statistics of other subspecialties.1,2 One of the challenges cited most consistently by young adult patients and their families relates to differences between rheumatology care delivery in the pediatric and…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:adalimumabPsoriatic Arthritisupadacitinib

COVID-19 & Pediatric Rheumatology

Elizabeth Sloan, MD  |  September 14, 2021

PRSYM 2021—Although primary COVID-19 infection has the most significant complications in adult patients, pediatric rheumatologists have also seen significant changes in their practice over the past year. With the emergence of COVID-19, the rise of a mysterious post-COVID hyper­inflammatory syndrome, now known as multisystem inflammatory syndrome in children (MIS-C), was identified, and pediatric rheumatologists have…

Filed under:ConditionsPediatric Conditions Tagged with:COVID-19Multisystem Inflammatory Syndrome in Children (MIS-C)PRSYM

EU Approves Tofacitinib Citrate for 2 Pediatric Conditions

Michele B. Kaufman, PharmD, BCGP  |  September 8, 2021

The European Commission approved tofacitinib citrate to treat two pediatric conditions, as well as a prolonged-release version of the medication designed to treat adults with active PsA.

Filed under:ConditionsDrug UpdatesPediatric ConditionsPsoriatic Arthritis Tagged with:drug approvalsEuropeEuropean Unionjuvenile idiopathic arthritis (JIA)juvenile PsAPediatricPediatric RheumatologyPsAPsoriatic Arthritistofacitinib citrate

Washington Pediatric Rheumatologists Eligible for Loan Forgiveness

Joseph Cantrell, JD  |  September 3, 2021

The 2021–23 Washington budget enables consideration of pediatric rheumatologists for state loan forgiveness programs during the 2019–21 and 2021–23 cycles, making it the first state to include any rheumatologists in its loan forgiveness programs.

Filed under:Legislation & AdvocacyWorkforce Tagged with:ACR advocacyloan forgivenessPediatric RheumatologyPediatric Subspecialty Loan ForgivenessState and local updatestate loan forgiveness billWashington

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 109
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences